Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

TRANS-FUSIMO · Clinical Translation of Patient-Specific Planning and Conduction of FUS Treatment in Moving Organs

FP7Status: CLOSED1 January 201431 December 2018EU funding €4,049,999

MR-guided Focused Ultrasound Surgery (MRgFUS) combines high intensity focused ultrasound for thermal ablation of diseased tissue with MR imaging to visualise the tumour and surrounding anatomy and to provide MR thermal feedback.However, MRgFUS treatment of the liver and other abdominal organs present tremendous technological challenges, including motion due to breathing and shielding of the target by the rib cage.To tackle these challenges, the VPH project FUSIMO has set out to develop a planning system for MRgFUS capable to deal with moving abdominal organs.TRANS-FUSIMO will translate the FUSIMO demonstrator into a clinically applicable system spanning the full clinical workflow of planning, conduction and assessment as well as learning from the procedure:1) Extension of the FUSIMO demonstrator to support conduction and assessment of the intervention under breathing motion2) Interfacing state-of-the-art FUS hardware and imaging devices to build an integrated real-time-capable system for liver FUS3) Improving model components for optimized clinical workflow, real-time applicability and validated outcome prediction4) Allowing training and learning using the FUSIMO software system by building a case and result database5) Conduction of pre-clinical (phantoms, cadaver, animal) experiments of the FUSIMO systemIn a clinical trial, the feasibility of using the integrated system for neoadjuvant MRgFUS to achieve prolonged survival will be investigated.As a final project result, the integrated system will be close to certification status and subsequent commercialization. With such an integrated real-time system, FUS can become a commercially and clinically competitive alternative to current surgical and minimal-invasive oncological interventions, thus providing a non-invasive treatment, reducing side-effects, and healthcare costs.

Consortium · 11 organisations

coordinator

FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV

DE · €1,063,446

participant

GE MEDICAL SYSTEMS ISRAEL LTD

IL · €179,880

participant

STIFTELSEN SINTEF

NO · €350,625

participant

INSIGHTEC LTD

IL · €354,814

participant

UNIVERSITY OF DUNDEE

UK · €779,859

participant

MEDIRI GMBH

DE · €282,860

participant

UNIVERSITA DEGLI STUDI DI PALERMO

IT · €153,600

participant

EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH

CH · €360,771

participant

JOHANN WOLFGANG GOETHE-UNIVERSITAET FRANKFURT AM MAIN

DE · €36,264

participant

IBSmm Engineering spol. s r. o.

CZ · €131,940

participant

UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA

IT · €355,940

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.